Clinical Trials | February 13, 2024
Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr
These re-agent and diagnostic test kits come with 99.7% accuracy
These re-agent and diagnostic test kits come with 99.7% accuracy
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Automated parallel capillary electrophoresis system simplifies protein analysis
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Subscribe To Our Newsletter & Stay Updated
